iBio

iBio CROIC

The Cash Return on Invested Capital (CROIC) of iBio (IBIO) as of Nov 17, 2026 is -27.07 %. In the previous year, Cash Return on Invested Capital (CROIC) was -83.32 % — a change of -67.51% (higher).

CROIC

-27.07 %

YoY

-67.51%

Last updated:

Cash Return on Invested Capital (CROIC) of iBio is 2026 -27.07 % . Cash Return on Invested Capital (CROIC) of iBio was 2025 -83.32 % . It decreases by -67.51% higher compared to the previous year.

The iBio CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
-54.72 USD
Jan 1, 2020
-16.20 USD
Jan 1, 2021
-24.93 USD
Jan 1, 2022
-50.57 USD
Jan 1, 2023
-111.46 USD
Jan 1, 2024
-72.77 USD
Jan 1, 2025
-83.32 USD
Jan 1, 2026
-27.07 USD
The iBio CROIC history
YEARCROICYoY
-27.07 %-67.51%
-83.32 %+14.49%
-72.77 %-34.71%
-111.46 %+120.42%
-50.57 %+102.85%
-24.93 %+53.93%
-16.20 %-70.40%
-54.72 %+55.03%
-35.30 %-18.24%
-43.17 %+87.61%
-23.01 %-47.68%
-43.99 %-38.68%
-71.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iBio Stock analysis

What does iBio do? iBio, Inc. generates revenue through the commercialization of its plant-based protein expression technologies, which are used for developing vaccines and therapeutic proteins. The company's iBioLaunch technology and iBioModulator platform enable the production of biologics in hydroponically grown green plants, targeting fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of plasma-derived products. Clients and collaborators purchase product development and manufacturing services, leveraging iBio's transformative platform for biologics production. The firm focuses on both its own product candidates and providing services to external partners in the biopharmaceutical sector. iBio's business model centers on offering its proprietary technologies as a service to clients, with a focus on developing and manufacturing biologics through plant-based systems. The company's technologies are applicable across multiple therapeutic areas, including fibrotic disease treatments, vaccine development, and enzyme replacement therapies. By providing these services, iBio supports clients in creating advanced biopharmaceutical products without the need for traditional manufacturing infrastructure. The company's revenue streams include the sale of its iBioLaunch and iBioModulator platforms, as well as product development and manufacturing services for biopharmaceutical clients. These services are tailored to meet the needs of partners seeking efficient, scalable production methods for biologics. iBio's focus on plant-based production differentiates it in the market, appealing to clients looking for innovative approaches to biologic manufacturing. iBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iBio stock

Cash Return on Invested Capital (CROIC) of iBio is -27.07 % in 2026.

Cash Return on Invested Capital (CROIC) of iBio changed from -83.32 % to -27.07 %, representing a -67.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) iBio since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s iBio with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — iBio

All Key Metrics — iBio